Silva, Renante S.
HRN: 09-04-48 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/30/2022
CO-AMOXICLAV 625MG (TAB)
06/30/2022
07/07/2022
PO
625
BID
Multiple Abrassions
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes